Relcovaptan
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
Synonyms | (2S)-1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indole-2-carbonyl]pyrrolidine-2-carboxamide |
CAS Number | 150375-75-0 |
PubChem (CID) | 60943 |
IUPHAR/BPS | 2200 |
ChemSpider | 54910 |
UNII | C1GL8G6G0O |
ChEMBL | CHEMBL419667 |
Chemical and physical data | |
Formula | C28H27Cl2N3O7S |
Molar mass | 620.501 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1a subtype.[1] It has shown positive initial results in tests against Raynaud's disease, dysmenorrhoea, and tocolysis,[2] although it is not yet approved for clinical use.
References
- ↑ Lemmens-Gruber R, Kamyar M. Vasopressin antagonists. Cellular and Molecular Life Sciences. 2006 Aug;63(15):1766-79. PMID 16794787
- ↑ Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008 May 10;371(9624):1624-32. PMID 18468546
This article is issued from Wikipedia - version of the 9/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.